Uburyo bwo kuvura indwara ya CAR-T ku ndwara ya Lymphoma itari iya Hodgkin (NHL)

Lymphoma itari iya Hodgkin (NHL) ni itsinda ry’ubwoko butandukanye bwa kanseri y’amaraso ikomoka mu mitsi, hamwe n’ubwoko butandukanye, harimo kanseri ya B-cell na T-cell. Muri zo, Lymphoma nini ya B-cell (DLBCL) ikwirakwira mu buryo butunguranye ni bwo bwoko bukunze kugaragara cyane kandi bukabije bwa NHL ya B-cell. Nubwo hari iterambere mu mikorere ya chimiotherapie na immunotherapy, abarwayi benshi ba NHL yasubiye inyuma cyangwa idakira barwana n'uburyo buke bwo kuvura. Ubuvuzi bwa CAR-T itanga uburyo bushya bwo kuvura indwara ya lymphoma, itanga icyizere ku barwayi bafite lymphoma itarakira uburyo gakondo bwo kuvura.

CAR-T (Chimeric Antigen Receptor T-cells) ni uburyo bushya bwo kuvura indwara ziterwa n’umubiri bukoresha uburyo bwo guhindura uturemangingo twa T tw’umurwayi kugira ngo tugaragaze uburyo bwo kuvura bwibasira uturemangingo twa kanseri. Kuri NHL, CAR-T therapy yibasira cyane cyane CD19 na CD20 Antigens ku tunyangingo twa B, zikunze kuboneka ku tunyangingo twa lymphoma mbi. Mu kongera ubushobozi bwa T-cells bwo kumenya no kwibasira utwo tunyangingo twa kanseri, ubuvuzi bwa CAR-T butanga uburyo bwiza bwo kuvura abarwayi ba lymphoma yasubiwemo cyangwa idashobora kugaragara.

• Ifite akamaro kuri NHL yo gusubira inyuma no kutagira ubushake bwo guhangana n'indwara ya Refractory: Ubuvuzi bwa CAR-T bwagaragaje imikorere idasanzwe ku barwayi ba DLBCL n'ubundi bwoko bwa B-cell NHL batakiriye uburyo bwinshi bwo kuvurwa.
• Uburyo bwo Kwita ku ntego: Ubu buvuzi bwibasira uturemangingo twa kanseri B tudakoze ku turemangingo tuzima, bigabanya ingaruka mbi zikunze kujyana n'ubuvuzi gakondo.
• Uburyo bwo kuvura bwite: Ubuvuzi bwa CAR-T bukoresha uturemangingo twa T tw'umurwayi, butanga uburyo bwo kuvura bwihariye bujyanye n'imiterere y'umuntu.
• Ishobora gutuma habaho igabanyirizwa ry'ikiguzi mu gihe kirekire: Abarwayi benshi bakize burundu cyangwa igice cy’indwara nyuma yo kuvurwa na CAR-T, bamwe bagakomeza kubaho igihe kirekire, ndetse no nyuma yo guhabwa imiti igabanya ubukana inshuro nyinshi.

• Gukusanya utunyangingo twa T: Uturemangingo twa T dukururwa mu maraso y'umurwayi binyuze mu buryo bwitwa leukapheresis, nk'uko bitangwa mu gutanga amaraso.
• Gutunganya uturemangingo twa T: Muri laboratwari, uturemangingo twa T twakusanyijwe turahindurwa kugira ngo tugaragaze neza uduce tw’umubiri twibasira antigen runaka nka CD19 cyangwa CD20 iboneka ku turemangingo twa lymphoma.
• Infusion ya CAR-T: Iyo uturemangingo twa T tumaze kwaguka no guhinduka, twongera gushyirwa mu maraso y'umurwayi kugira ngo twibasire uturemangingo twa lymphoma.
• Gukurikirana no Gusubiza mu buzima busanzwe: Nyuma yo guterwa umuti, abarwayi bakurikiranwa kugira ngo barebe ingaruka mbi, nka cytokine release syndrome (CRS) ndetse n'uburozi bw'imitsi, byombi bishobora gukemurwa n'ubuvuzi bukwiye.

• Ikoranabuhanga rigezweho rya CAR-T: BIOOCUS ikoresha ikoranabuhanga rigezweho rya CAR-T kugira ngo itange ubuvuzi bugezweho kandi bufite akamaro kuri NHL, ikoresheje ubushakashatsi bugezweho kugira ngo ibone umusaruro mwiza.
• Itsinda ry'impuguke mu bijyanye n'indwara z'amaraso: Itsinda ryacu ry’inzobere mu by’amaraso, abaganga b’inzobere mu kuvura kanseri y’amaraso n’inzobere mu buvuzi bw’umubiri bakorana kugira ngo batange gahunda z’ubuvuzi bwihariye kuri buri murwayi.
• Intsinzi yagaragaye mu kuvura DLBCL: BIOOCUS yavuje abarwayi benshi ba NHL ikoresheje CAR-T therapy, igera ku mpungenge zitangaje, harimo no koroherwa burundu no kubaho igihe kirekire, cyane cyane ku barwayi ba DLBCL basubiye inyuma cyangwa badafite ubushobozi bwo kuvura.
• Ubufasha bwuzuye bw'abarwayi: Kuva ku nama ya mbere kugeza ku buvuzi nyuma yo kuvurwa, BIOOCUS itanga ubufasha bwuzuye ku barwayi mpuzamahanga, bigatuma urugendo rwabo rworoshye kandi rubafasha mu gihe cyose bavurwa.

• Ubuvuzi bwa CAR-T kuri NHL, cyane cyane kuri DLBCL, bwagaragaje umusaruro mwiza mu igeragezwa ry’ubuvuzi no mu bikorwa nyabyo. Ku barwayi bagiye bavurwa inshuro nyinshi ariko ntibagire icyo bageraho, ubuvuzi bwa CAR-T bwagaragaye ko ari uburyo bwo kurokora ubuzima.

  • Inkuru y'umurwayi: Lymphoma nini ya B-cell (DLBCL) ikwirakwira—Gukira gutangaje nyuma yo kuvurwa na CAR-T
  • Intsinzi mu buvuzi: Ubuvuzi bwa CAR-T kuri DLBCL yasubitse ku barwayi—Inzira yo kwihanagura burundu
  • DLBCL Idakira Imirongo Minini: Inyigo y'Icyitegererezo ku Ngaruka z'Ubuvuzi bwa CAR-T muri Lymphoma Iteye Imbere

  Ubu bushakashatsi bwerekana ubushobozi bwo guhindura ubuvuzi bwa CAR-T ku barwayi ba NHL, cyane cyane abafite DLBCL irwanya imiyoboro myinshi. Abarwayi benshi bakize igihe kirekire kandi bongera kugira ubuzima bwiza nyuma yo kuvurwa.

Ibimenyetso bya CD19+20CAR-T:Abarwayi bafite lymphoma ya B-cell non Hodgkin

Ibimenyetso bya CD19+22CAR-T:Kuvura abarwayi ba kanseri y'amaraso ya B-lymphocytic basubiye inyuma kandi badafite CD19

Ibimenyetso bya BCMACAR-T:Kuvura myeloma nyinshi yasubiwemo kandi idashobora kuvura